SCHEMBL2531178

SCHEMBL2531178

C=CCN(C(=O)OCc1ccccc1)c1cc(C=O)cc(C(=O)OC)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.42
LMNA P02545 1/20 0.42
RAB9A P51151 3/20 0.41
ALDH1A1 P00352 8/20 0.40
MAPT P10636 2/20 0.40
KDM4E B2RXH2 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
TSHR P16473 3/20 0.40
NPC1 O15118 1/20 0.40
GAA P10253 1/20 0.40
MAPK1 P28482 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CYP3A4 P08684 2/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A3 Q01959 1/20 0.36
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CCR6 P51684 1/20 0.35
PAX8 Q06710 1/20 0.35
PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4651101 0.92 CYP3A4 (0.37) HPGDLMNARAB9AALDH1A1MAPT
SCHEMBL4878311 0.89 HPGD (0.47) HPGDLMNARAB9AALDH1A1MAPT
SCHEMBL4754720 0.88 KDM4E (0.35) HPGDLMNARAB9AALDH1A1MAPT
SCHEMBL2532552 0.88 HPGD (0.44) HPGDLMNARAB9AALDH1A1MAPT
SCHEMBL2533468 0.87 ALDH1A1 (0.43) HPGDLMNARAB9AALDH1A1MAPT
SCHEMBL2526880 0.87 TSHR (0.47) HPGDLMNARAB9AALDH1A1MAPT
SCHEMBL2530507 0.87 ALDH1A1 (0.43) HPGDLMNARAB9AALDH1A1MAPT
SCHEMBL2527578 0.86 ALDH1A1 (0.43) HPGDLMNARAB9AALDH1A1MAPT
SCHEMBL4877948 0.86 ALDH1A1 (0.43) HPGDLMNARAB9AALDH1A1MAPT
SCHEMBL4872892 0.84 RAB9A (0.42) HPGDLMNARAB9AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8039455-B2 Macrocyclic compounds useful as BACE inhibitors NOVARTIS AG (CH) 2011-10-18 US disclosed
US-20090029960-A1 MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS NOVARTIS AG (CH) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029960-A1 MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS SLC10A2, SLC10A1, ASAH2 HPGD 889/4885LMNA 1336/4885RAB9A 2614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.